DelveInsight Releases Report on Gastrointestinal Stromal Tumor Pipeline
Market research firm DelveInsight has published a report assessing the development pipeline for gastrointestinal stromal tumor (GIST) treatments. The report covers over 22 companies and 25 late-stage drug candidates.
Market research firm DelveInsight has released its "Gastrointestinal stromal tumor Pipeline Insight, 2026" report, offering a comprehensive overview of the global development landscape for gastrointestinal stromal tumor (GIST) treatments. The report details the activities of over 22 companies and the status of more than 25 drug candidates, spanning both clinical and non-clinical stages.
GIST is a rare malignancy originating in the gastrointestinal tract, often driven by mutations in the KIT or PDGFRA genes. Key treatment modalities include surgical resection and tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, regorafenib, ripretinib, and avapritinib.
The DelveInsight report assesses pipeline drug candidates based on product type, stage, route of administration, and molecule type. It aims to provide in-depth insights into drug mechanisms of action, clinical studies, and product development activities, including collaborations, licensing deals, and funding.
The report also highlights inactive or discontinued development projects within the GIST therapeutic area. The analysis covers the global market and offers information relevant to companies and healthcare professionals seeking to understand the evolving treatments for this rare disease.